OLD Category: signatures

Cell of origin of transformed follicular lymphoma

• Kridel R. et al.,

Phase II Study of Bevacizumab, Temozolomide and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma

• Omuro A. et al.,

Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma

• Chen D.T. et al.,

Clinicopathological indices to predict hepatocellular carcinoma molecular classification

• Tan P.S. et al.,

Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial

• Sandmann T. et al.,

Developing Molecular Signatures for Chronic Lymphocytic Leukemia

• Cornet E. et. al.,

Characterization of a novel chicken muscle disorder through differential gene expression and pathway analysis using RNA-sequencing

• Mutryn M.F. et al.,

Up-Regulation of Periostin and Reactive Stroma is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer

• Ryner L. et al.,

SOX4, SOX11 and PAX6 mRNA expression was identified as a (prognostic) marker for the aggressiveness of neuroendocrine tumors of the lung by using next-generation expression analysis (NanoString)

• Walter R.F.H. et al.,

Deregulation of the FOXM1 target gene network and its coregulatory partners in oesophageal adenocarcinoma

• Wiseman E.F. et al.,

Efficient molecular subtype classification of high-grade serous ovarian cancer

• Leong H.S. et al.,

Identification of new biomarkers for human papillary thyroid carcinoma employing NanoString analysis

• Chitikova Z. et al.,